Dexcom insider plans Rule 144 share sale

Dexcom insider Bridgette P. Heller filed a notice of proposed sale under Rule 144 covering 1,012 shares of common stock, with an aggregate market value of 68826.12.

Rhea-AI Filing Summary

Dexcom insider Bridgette P. Heller filed a notice of proposed sale under Rule 144 covering 1,012 shares of common stock, with an aggregate market value of 68826.12. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ around 02/12/2026.

The securities were originally acquired on 09/29/2021 via restricted stock vesting as compensation. The filing also notes a prior sale on 11/12/2025 of 1,012 shares for gross proceeds of 58766.84. Dexcom had 390,016,272 shares outstanding when this notice was prepared.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the DXCM Form 144 filing by Bridgette P. Heller show?

The Form 144 shows Bridgette P. Heller intends to sell 1,012 Dexcom common shares under Rule 144. The shares were acquired via restricted stock vesting in 2021, and the planned sale is through Fidelity Brokerage Services on NASDAQ around 02/12/2026.

How many Dexcom (DXCM) shares are covered by this Form 144?

The notice covers a proposed sale of 1,012 Dexcom common shares. The filing lists an aggregate market value of about 68826.12 for this planned transaction, with trading expected on NASDAQ through Fidelity Brokerage Services as the executing broker.

When did the DXCM insider originally acquire the shares being sold?

The filing states the 1,012 shares were acquired on 09/29/2021 through restricted stock vesting. The consideration is described as compensation from the issuer, indicating these shares were part of an equity award rather than a cash purchase in the market.

What prior Dexcom (DXCM) share sales by this insider are disclosed?

The document reports a prior sale on 11/12/2025 of 1,012 Dexcom common shares, generating gross proceeds of 58766.84. This disclosure covers securities sold during the past three months for the same account, as required by Rule 144.

How many Dexcom (DXCM) shares were outstanding according to this notice?

The Form 144 lists 390,016,272 Dexcom common shares outstanding. This figure provides context for the relative size of the 1,012-share proposed sale, though it does not change the number of shares covered by the insider’s Rule 144 notice.

On which exchange will the Dexcom (DXCM) Rule 144 shares be sold?

The planned transaction identifies NASDAQ as the securities exchange for the 1,012 Dexcom common shares. Fidelity Brokerage Services LLC is listed as the broker handling the sale, with an approximate sale date of 02/12/2026 in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 09:51 AM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001485616
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DEXCOM INC
SEC File Number	000-51222
Address of Issuer	6340 SEQUENCE DRIVE SAN DIEGO CALIFORNIA 92121
Phone	8582000200
Name of Person for Whose Account the Securities are To Be Sold	Heller Bridgette P
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1012	68826.12	390016272	02/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/29/2021	Restricted Stock Vesting	Issuer			1012	09/29/2021	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Bridgette P. Heller 6340 Sequence Drive San Diego CA 92121	Common	11/12/2025	1012	58766.84

144: Remarks and Signature

Remarks
Date of Notice	02/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Bridgette P. Heller
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)